Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer

Acta Oncologica

Volumn 46, Issue 7, 2007, Pages 937-944

  Gunnlaugsson, Adalsteinn ^a   Kjellén, Elisabeth ^a   Nilsson, Per ^a   Bendahl, Pär Ola ^a   Willner, Julian ^a   Johnsson, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; ENTERITIS; ENTEROSTOMY; FEMALE; HISTOGRAM; HUMAN; HYPERTENSION; LARGE INTESTINE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION ENTEROPATHY; RATING SCALE; RECTUM CANCER; RETROSPECTIVE STUDY; SMALL INTESTINE; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENTERITIS; FEMALE; FLUOROURACIL; HUMANS; INTESTINE, LARGE; INTESTINE, SMALL; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RADIATION INJURIES; RECTAL NEOPLASMS;

EID: 35148893255     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701317873     Document Type: Article

References (28)

1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351: 1731-40.
2. Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L, Maingon P, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: Assessment of acute toxicity and treatment compliance, report of the 22 921 randomized trial conducted by the EORTC radiotherapy group. Eur J Cancer 2004;40:219-24.
3. Brændengen M, Tveit KM, Berglund Å, Birkemeyer E, Frykholm G, Pa° hlman L, et al. A randomized phase III study (LARCS) comparing preoperative radiotherapy alone versus chemoradiotherapy in non-resectable rectal cancer. ECCO 13-the European Cancer Conference 2005;[Abstract #612].
4. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
5. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan P, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
6. Källström J, Kjellén E, Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol 2005;44:687-93.
7. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll H-J, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;20:3098-104.
8. Machiels JP, Duck L, Honhon B, Coster B, Coche J-C, Scalliet P, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: The radioxcape study. Ann Oncol 2005;16: 1898-905.
9. Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG et al. Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001;40:515-22.
10. Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand S, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum. A progress report of the National Surgical Adjuvant Breast an Bowel Project Protocol R-03. Dis Colon Rectum 1997;40:131-9.
11. Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 1995;13:1409-16.
12. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:176-83.
13. Tho LM, Glegg M, Paterson J, Yap C, MacLeod A, McCabe M, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006;66:505-13.
14. Sørbye H, Glimelius B, Berglund Å, Fokstuen T, Tveit KM, Brændegen M, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31-8.
15. International Commission of Radiation Units and Measurements. ICRU report 50: Prescribing, recording and reporting photon beam therapy. Bethesda: International Commission of Radiation Units and Measurements; 1993.
16. International Commission on Radiation Units and Measurements. ICRU report 62: Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). Bethesda: ICRU; 1999.
17. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Phys 2000;47: 13-47.
18. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985;8:S13-9.
19. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. Int J Radiat Oncol Biol Phys 1989; 16:1623-30.
20. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-35.
21. Källman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol 1992;62:249-62.
22. Niemierko A. A generalized concept of Equivalent Uniform Dose (EUD). Med Phys 1999;26:1101.
23. Muren LP, Jebsen N, Gustafsson A, Dahl O. Can dose-response models predict reliable normal tissue complication probabilities in radical radiotherapy of urinary bladder cancer? The impact of alternative radiation tolerance models and parameters. Int J Radiat Oncol Biol Phys 2001;50:627-37.
24. Muren LP, Hafslund R, Gustafsson A, Smaaland R, Dahl O. Partially wedged beams improve radiotherapy treatment of urinary bladder cancer. Radiother Oncol 2001;59: 21-30.
25. Touboul E, Balosso J, Schlienger M, Laugier A. Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention. Ann Chir 1996;50: 58-71.
26. Koelbl O, Richter S, Flentje M. Influence of patient positioning on dose-volume histogram and normal tissue complication probability for small bowel and bladder in patients receiving pelvic irradiation: A prospective study using a 3D planning system and a radiobiological model. Int J Radiat Oncol Biol Phys 1999;45:1193-8.
27. Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank LE, Gehring MA, et al. Minimization of small bowel volume within treatment fields utilizing customized "belly boards". Int J Radiat Oncol Biol Phys 1990;19:469-76.
28. Huh SJ, Lim DH, Ahn YC, Kim DY, Kim MK, Wu HG, et al. Effect of customized small bowel displacement system in pelvic irradiation. Int J Radiat Oncol Biol Phys 1988;40: 623-7.